Form 4: Avadel Pharmaceuticals Director Linda Palczuk Reports Stock Option Transfer to Trust
SEC Filing
Director Linda Palczuk reported transferring 11,000 stock options to a revocable trust on September 15, 2024.
Summary
- On September 16, 2024, a Form 4 filing was submitted to the SEC regarding Linda Palczuk, a director of Avadel Pharmaceuticals PLC.
- The filing reports a transaction on September 15, 2024, where Ms. Palczuk transferred 11,000 stock options to a revocable trust.
- The options have an exercise price of $16.32 and vest fully on the earlier of July 30, 2025, or the date of the next annual general meeting following July 30, 2024, contingent upon continued service.
- The expiration date for the options is July 30, 2034.
- Following the transaction, Ms. Palczuk directly owns 0 options and indirectly owns 11,000 options through the trust.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Industry Context
Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders.
Key Dates
| Date | Description |
|---|---|
| July 30, 2024 | Date of grant for the stock options. |
| September 15, 2024 | Date of the stock option transfer to the revocable trust. |
| September 16, 2024 | Date the Form 4 was filed. |
| July 30, 2025 | One of the dates on which the options vest. |
| July 30, 2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.